A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Mar 2025 According to a Protagonist Therapeutics media release, the company is working with our partner, Takeda, to submit our findings to the regulatory agencies. Protagonist is under a license and collaboration agreement with Takeda, under which Protagonist earns a $25 million milestone payment following these positive results. The milestone is payable following completion of the VERIFY clinical study report.
03 Mar 2025 European primary endpoint (Comparison of mean number of phlebotomies between rusfertide and placebo) has been met.
03 Mar 2025 The first key secondary endpoint, which is the pre-specified primary endpoint for European Union (EU) regulators, was Comparison of mean number of phlebotomies between rusfertide and placebo, and it was met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com